Therapeutic monitoring of plasma clozapine and N-desmethylclozapine (norclozapine): practical considerations

SUMMARY Clozapine dose assessment in treatment-refractory schizophrenia is complicated. There is a narrow margin between an effective and a potentially toxic dose and wide inter-individual variation in clozapine metabolic capacity. Moreover, factors such as changes in smoking habit, infection/inflammation, co-prescription of certain drugs, notably fluvoxamine, and age alter the dose requirement within individuals. Therapeutic drug monitoring (TDM) of plasma clozapine and N-desmethylclozapine (norclozapine) can help assess adherence, guide dosage and guard against toxicity. This article gives an overview of clozapine pharmacokinetics and factors affecting clozapine dose requirements. It then outlines the procedures and processes of clozapine TDM, from taking the blood sample for laboratory assay or point-of-contact (finger-prick) testing (POCT) to interpreting and acting on the results.

[1]  S. Reeves,et al.  Clozapine: Dose, Sex, Ethnicity, Smoking Habit, Age, Body Weight, and Plasma Clozapine and N-Desmethylclozapine (Norclozapine) Concentrations in Clinical Practice. , 2023, Journal of clinical psychopharmacology.

[2]  P. Gourzis,et al.  Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Review , 2022, Pharmaceuticals.

[3]  S. Reeves,et al.  Plasma Clozapine and Norclozapine After Use of Either Crushed Tablets or Suspension Compared With Tablets , 2022, Journal of clinical psychopharmacology.

[4]  A. Serretti,et al.  Dried Volumetric Microsampling Approaches for the Therapeutic Drug Monitoring of Psychiatric Patients Undergoing Clozapine Treatment , 2022, Frontiers in Psychiatry.

[5]  D. Hesselink,et al.  Best Practices to Implement Dried Blood Spot Sampling for Therapeutic Drug Monitoring in Clinical Practice , 2022, Therapeutic drug monitoring.

[6]  L. Dratcu,et al.  First Use of Clozapine Point of Care Testing in Acute Inpatient Psychiatry: Preliminary Report. , 2022, Journal of Psychiatric Practice.

[7]  M. Sanches,et al.  Reliability of the clozapine: N-desmethylclozapine (CLZ: NDMC) ratio , 2021, Schizophrenia Bulletin Open.

[8]  K. Johnson-Davis,et al.  Multi-Site Evaluation of Immunoassays for Antipsychotic Drug Measurement in Clinical Samples. , 2021, The Journal of Applied Laboratory Medicine.

[9]  E. V. van Puijenbroek,et al.  Body weight gain in clozapine‐treated patients: Is norclozapine the culprit? , 2021, British journal of clinical pharmacology.

[10]  P. McGuire,et al.  Point-of-care measurement of clozapine concentration using a finger-stick blood sample , 2021, Journal of psychopharmacology.

[11]  D. Siskind,et al.  A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions , 2021, Psychopharmacology.

[12]  Xu Wang,et al.  Metabolism and mechanism of human cytochrome P450 enzyme 1A2. , 2021, Current drug metabolism.

[13]  P. Falkai,et al.  Impact of smoking behavior on clozapine blood levels – a systematic review and meta‐analysis , 2020, Acta psychiatrica Scandinavica.

[14]  D. Kelly,et al.  Comparison of Novel Immunoassay with Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) for Therapeutic Drug Monitoring of Clozapine. , 2020, Therapeutic drug monitoring.

[15]  J. de Leon,et al.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology , 2020, Psychotherapy and Psychosomatics.

[16]  B. Ibrahim,et al.  Population Pharmacokinetics of Clozapine: A Systematic Review , 2020, BioMed research international.

[17]  D. Kelly,et al.  Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes , 2019, Neuropsychiatric disease and treatment.

[18]  L. Couchman,et al.  Changes in smoking status, mental state and plasma clozapine concentration: retrospective cohort evaluation , 2019, BJPsych bulletin.

[19]  F. Gaughran,et al.  Treatment resistant schizophrenia – review and a call to action , 2018, Irish Journal of Psychological Medicine.

[20]  Russ B. Altman,et al.  PharmGKB summary: clozapine pathway, pharmacokinetics , 2018, Pharmacogenetics and genomics.

[21]  D. Fisher,et al.  Clozapine and Norclozapine Concentrations in Paired Human Plasma and Serum Samples , 2017, Therapeutic drug monitoring.

[22]  D. Cohen,et al.  Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine. , 2017, The Journal of clinical psychiatry.

[23]  J. Leon.  A Critical Commentary on the 2017 AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology. , 2017 .

[24]  K Domschke,et al.  Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 , 2017, Pharmacopsychiatry.

[25]  R. Lentle,et al.  Spatiotemporal Mapping Techniques Show Clozapine Impairs Neurogenic and Myogenic Patterns of Activity in the Colon of the Rabbit in a Dose-Dependent Manner , 2017, Front. Pharmacol..

[26]  S. Seedat,et al.  Measurement of Clozapine, Norclozapine, and Amisulpride in Plasma and in Oral Fluid Obtained Using 2 Different Sampling Systems , 2017, Therapeutic drug monitoring.

[27]  A. Fink-Jensen,et al.  The significance of sampling time in therapeutic drug monitoring of clozapine , 2017, Acta psychiatrica Scandinavica.

[28]  O. Howes,et al.  Optimising treatment of schizophrenia: the role of adjunctive fluvoxamine , 2016, Psychopharmacology.

[29]  P. Azzam,et al.  Suspected Secondhand Smoke and Clozapine Toxicity. , 2015, Psychosomatics.

[30]  John Lally,et al.  Antipsychotic medication in schizophrenia: a review. , 2015, British medical bulletin.

[31]  R. Dufresne,et al.  A review of the clinical utility of serum clozapine and norclozapine levels , 2015 .

[32]  A. Batra,et al.  Clozapine serum concentrations in dopamimetic psychosis in Parkinson’s disease and related disorders , 2014, European Journal of Clinical Pharmacology.

[33]  Lewis Couchman,et al.  A novel approach to quantitative LC-MS/MS: therapeutic drug monitoring of clozapine and norclozapine using isotopic internal calibration , 2013, Analytical and Bioanalytical Chemistry.

[34]  D. Fisher,et al.  Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum. , 2013, Forensic science international.

[35]  J. Swales,et al.  The stability of amitriptyline N-oxide and clozapine N-oxide on treated and untreated dry blood spot cards. , 2013, Journal of pharmaceutical and biomedical analysis.

[36]  Anju Kuruvilla,et al.  Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia , 2013, International clinical psychopharmacology.

[37]  L. Couchman,et al.  Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996–2010 , 2012, Human psychopharmacology.

[38]  J. Arrang,et al.  Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo , 2012, Psychopharmacology.

[39]  Lewis Couchman,et al.  Plasma Clozapine, Norclozapine, and the Clozapine:Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993–2007 , 2010, Therapeutic drug monitoring.

[40]  H. Refsum,et al.  The effect of variable cigarette consumption on the interaction with clozapine and olanzapine , 2006, European Journal of Clinical Pharmacology.

[41]  U. Fuhr,et al.  Time response of cytochrome P450 1A2 activity on cessation of heavy smoking , 2004, Clinical pharmacology and therapeutics.

[42]  Amin Rostami-Hodjegan,et al.  Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine Concentrations: A Predictive Model and Nomograms to Aid Clozapine Dose Adjustment and to Assess Compliance in Individual Patients , 2004, Journal of clinical psychopharmacology.

[43]  B. Urquhart,et al.  Monitoring Clozapine: Are Fingerprick Blood and Plasma Clozapine Levels Equivalent to Arm Venipuncture Blood and Plasma Levels? , 2003, Therapeutic drug monitoring.

[44]  R. Flanagan,et al.  Comparability of whole-blood and plasma clozapine and norclozapine concentrations. , 2003, British journal of clinical pharmacology.

[45]  K. Dietz,et al.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. , 1998, British journal of clinical pharmacology.

[46]  K. Midha,et al.  Decomposition of clozapine N-oxide in the qualitative and quantitative analysis of clozapine and its metabolites. , 1994, Journal of pharmaceutical sciences.

[47]  E. Fernandez-Egea,et al.  Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice. , 2019, Revista de Psiquiatría y Salud Mental.